- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
D
DYN
Dyne Therapeutics, Inc.
18.68
-0.68-3.51%After Hours: 18.70 +0.02 +0.13%16:52 04/10 EDT
OPEN/PREV CLOSE19.68/19.36
TODAY RANGE18.53-19.99
VOL1.24M
MARKET CAP3.09B
52 WEEK RANGE6.36-25.00
AVG VOL (3M)2.16M
% TURNOVER0.75%
TURNOVER--
P/E (TTM)-5.3771
% RANGE7.54%
EPS(TTM)-3.4740
P/E(FORWARD)-6.2447
P/B3.170
BVPS5.89
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.90B
SHARES OUTSTANDING165.22M
NEXT EARNINGS05/06-05/11
FREE FLOAT155.16M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·6d ago
A Look At Dyne Therapeutics (DYN) Valuation After Strong Recent Share Price Momentum
Simply Wall St·04/02 08:19
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
TipRanks·04/02 02:02
Insider Scoop: Dyne Therapeutics Director Makes a Bold New Purchase
Seeking Alpha·03/19 18:37
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Simply Wall St·03/16 23:24
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?
TipRanks·03/16 11:35
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)
Simply Wall St·03/14 18:36
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
TipRanks·03/14 02:08
Top Dyne Therapeutics Insider Quietly Boosts Stake in Bold New Move
Reuters·03/13 20:47
Dyne Therapeutics Director Brian S. Posner Acquires Common Shares
Reuters·03/13 20:36
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Simply Wall St·03/13 14:17
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data
Reuters·03/11 21:28
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Benzinga·03/10 15:06
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Same Industry